NasdaqGS - Nasdaq Real Time Price USD

Inhibrx Biosciences, Inc. (INBX)

12.33
+0.31
+(2.58%)
At close: May 16 at 4:00:02 PM EDT
12.33
0.00
(0.00%)
After hours: May 16 at 4:02:20 PM EDT
Advanced Chart
Loading Chart for INBX
  • Previous Close 12.02
  • Open 12.03
  • Bid 8.90 x 200
  • Ask 15.62 x 200
  • Day's Range 12.02 - 12.48
  • 52 Week Range 10.80 - 18.95
  • Volume 54,752
  • Avg. Volume 109,841
  • Market Cap (intraday) 178.488M
  • Beta (5Y Monthly) --
  • PE Ratio (TTM) 0.11
  • EPS (TTM) 112.62
  • Earnings Date Aug 11, 2025 - Aug 15, 2025
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 12.00

Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates include INBRX-109, a tetravalent therapeutic candidate targeting death-receptor 5 to treat unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-based therapeutic candidate targeting OX4 for the treatment of metastatic solid tumor, non-small cell lung cancer, melanoma, head and neck squamous cell carcinoma, gastric or gastroesophageal junction adenocarcinoma, renal cell carcinoma, and urothelial cell carcinoma. Inhibrx Biosciences, Inc. was incorporated in 2024 and is based in La Jolla, California.

inhibrx.com

156

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

More about Inhibrx Biosciences, Inc.

Recent News: INBX

View More
View More

Performance Overview: INBX

Trailing total returns as of 5/16/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

INBX
19.94%
S&P 500 (^GSPC)
1.30%

1-Year Return

INBX
33.17%
S&P 500 (^GSPC)
12.48%

3-Year Return

INBX
33.17%
S&P 500 (^GSPC)
48.66%

5-Year Return

INBX
33.17%
S&P 500 (^GSPC)
108.07%

Compare To: INBX

Compare

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

INBX
Inhibrx Biosciences, Inc.
12.33
+2.58%
Mkt Cap 178.488M
Industry Biotechnology
HOPHF
Hemogenyx Pharmaceuticals Plc
1.2400
0.00%
Mkt Cap 22.929M
Industry Biotechnology
PBYI
Puma Biotechnology, Inc.
3.3900
+3.35%
Mkt Cap 168.273M
Industry Biotechnology
ZBIO
Zenas BioPharma, Inc.
10.47
+7.49%
Mkt Cap 438.004M
Industry Biotechnology
RAPP
Rapport Therapeutics, Inc.
9.96
+2.10%
Mkt Cap 363.516M
Industry Biotechnology
ROIV
Roivant Sciences Ltd.
10.79
+0.28%
Mkt Cap 7.699B
Industry Biotechnology
MBX
MBX Biosciences, Inc.
11.16
+4.79%
Mkt Cap 373.016M
Industry Biotechnology
CGEM
Cullinan Therapeutics, Inc.
7.50
+3.59%
Mkt Cap 442.61M
Industry Biotechnology
SRRK
Scholar Rock Holding Corporation
30.55
-0.91%
Mkt Cap 2.901B
Industry Biotechnology
LYEL
Lyell Immunopharma, Inc.
0.4150
+3.31%
Mkt Cap 122.565M
Industry Biotechnology
BPMC
Blueprint Medicines Corporation
101.69
+2.21%
Mkt Cap 6.567B
Industry Biotechnology

Statistics: INBX

View More

Valuation Measures

Annual
As of 5/16/2025

  • Market Cap

    178.49M

  • Enterprise Value

    33.94M

  • Trailing P/E

    0.11

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    923.76

  • Price/Book (mrq)

    1.34

  • Enterprise Value/Revenue

    169.70

  • Enterprise Value/EBITDA

    0.02

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    861,485.55%

  • Return on Assets (ttm)

    -107.28%

  • Return on Equity (ttm)

    4,118.34%

  • Revenue (ttm)

    200k

  • Net Income Avi to Common (ttm)

    1.72B

  • Diluted EPS (ttm)

    112.62

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    216.52M

  • Total Debt/Equity (mrq)

    112.80%

  • Levered Free Cash Flow (ttm)

    -80.62M

View More

Research Analysis: INBX

View More
View More

Company Insights: INBX

Research Reports: INBX

View More
View More

People Also Watch

KROS Keros Therapeutics, Inc.
14.07
+0.29%
 
KYMR Kymera Therapeutics, Inc.
30.25
+0.77%
 
ITOS iTeos Therapeutics, Inc.
7.81
-2.01%
 
ZNTL Zentalis Pharmaceuticals, Inc.
1.2600
0.00%
 
FDMT 4D Molecular Therapeutics, Inc.
3.4400
+7.50%
 
HRMY Harmony Biosciences Holdings, Inc.
35.07
+2.45%
 
ORIC ORIC Pharmaceuticals, Inc.
4.7300
-0.21%
 
PCVX Vaxcyte, Inc.
31.85
+3.07%
 
PMVP PMV Pharmaceuticals, Inc.
0.8659
+3.32%
 
NRIX Nurix Therapeutics, Inc.
9.56
+1.06%
 
FHTX Foghorn Therapeutics Inc.
4.4300
+2.78%
 
PRAX Praxis Precision Medicines, Inc.
37.02
-0.48%
 
CGEM Cullinan Therapeutics, Inc.
7.50
+3.59%
 
GBIO Generation Bio Co.
0.3813
+1.52%
 
OLMA Olema Pharmaceuticals, Inc.
4.7100
+0.43%
 
IDYA IDEAYA Biosciences, Inc.
17.82
+2.95%